albumin binding comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-01-15. Numbers and descriptions here follow the published literature rather than marketing material.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
Downstream of growth hormone, the liver and other tissues increase production of insulin-like growth factor 1, a mediator of many growth-promoting effects. Studies have documented elevated levels of both hormones after dosing, and the rise from the long-acting form persists longer than that produced by shorter-acting analogues. What remains unclear is whether sustained elevation of these markers translates into meaningful clinical benefit, and whether prolonged exposure carries risks that short trials could not detect.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
==== Marketed ==== Dextromethorphan (DXM; Robitussin) Dextropropoxyphene (Darvon) Dimenhydrinate (Dramamine) Diphenhydramine (Benadryl) Mepyramine (pyrilamine) (Anthisan) Mifepristone (Korlym, Mifeprex)
Therapeutic drug monitoring (TDM) is a branch of clinical chemistry and clinical pharmacology that specializes in the measurement of medication levels in blood. Its main focus is on drugs with a narrow therapeutic range, i.e. drugs that can easily be under- or overdosed. TDM aimed at improving patient care by individually adjusting the dose of drugs for which clinical experience or clinical trials have shown it improved outcome in the general or special populations. It can be based on an a priori pharmacogenetic, demographic and clinical information, and/or on the a posteriori measurement of blood concentrations of drugs (pharmacokinetic monitoring) or biological surrogate or end-point markers of effect (pharmacodynamic monitoring). There are numerous variables that influence the interpretation of drug concentration data: time, route and dose of drug given, time of blood sampling, handling and storage conditions, precision and accuracy of the analytical method, validity of pharmacokinetic models and assumptions, co-medications and, last but not least, clinical status of the patient (i.e. disease, renal/hepatic status, biologic tolerance to drug therapy, etc.). Many different professionals (physicians, clinical pharmacists, nurses, medical laboratory scientists, etc.) are involved with the various elements of drug concentration monitoring, which is a truly multidisciplinary process.
== Early life and education == McGuire was born in Fayetteville, Arkansas, and grew up and graduated high school in Mountain Home, Arkansas. He earned a Bachelor of Arts in chemistry, summa cum laude and with Distinction from Hendrix College in Conway, Arkansas. He received his Doctor of Medicine from the Johns Hopkins University School of Medicine, where he was elected to the Alpha Omega Alpha Honor Medical Society. He completed his internship and residency in internal medicine at the University of Texas Southwestern Medical Center, followed by cardiology fellowship training at Duke University School of Medicine. He was a research fellow at the Duke Clinical Research Institute, where he was Chief Fellow from 1999 to 2000, and earned a Master of Health Sciences degree in clinical research.
=== 1950s === In 1953, the company became a public company via an initial public offering on the New York Stock Exchange. In 1954, the company acquired Davison Chemical Company and Dewey & Almy Chemical Company, entering the specialty chemicals and specialty materials industries and establishing the basis for the current product lines. In 1955, the company elected a chairman of the company who was not a member of the Grace family, which was a first in the 101-year history of company. The company appointed Charles E. Wilson, who was the former CEO of General Electric. His predecessor for his position was William Grace Holloway.
Sources: en.wikipedia.org
Subsequent activation of AMPA (α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid), NMDA (N-methyl-D-aspartate) and kainate subtypes of ionotropic glutamate receptors follows. It is the activation of these receptors that potentiates the pain signal up the spinal cord. This idea, although true, is an oversimplification of pain transduction. A litany of other neurotransmitter and neuromodulators, such as calcitonin gene-related peptide (CGRP), adenosine triphosphate (ATP), brain-derived neurotrophic factor (BDNF), somatostatin, vasoactive intestinal peptide (VIP), galanin, and vasopressin are all synthesized and released in response to noxious stimuli. In addition to each of these regulatory factors, several other interactions between pain-transmitting neurons and other neurons in the dorsal horn have added impact on pain pathways.
== History == Efficacy was evaluated in ARROS-1 (NCT05118789), a multi-center, single-arm, open-label, multi-cohort trial in participants with previously treated locally advanced or metastatic ROS1-positive NSCLC. The efficacy population included 117 participants; 59 who received one prior ROS1 tyrosine kinase inhibitor and 58 who received two or more prior ROS1 tyrosine kinase inhibitors, including lorlatinib, repotrectinib, and/or taletrectinib.
According to Panorama investigation, Daniel has operated in the boxing industry through MTK and simultaneously operated Europe's biggest money laundering, drug trafficking, and gangland executions networks from Dubai. A spokesperson for minister O'Brien said, "respect for human rights is a cornerstone of Ireland's foreign policy," when asked if the minister would raise the concerns regarding Daniel's presence and operations in Dubai on his visit in March 2022 for St Patrick's Day. The European Union placed the UAE on its money laundering blacklist, in December 2022. It implied that the EU considers the Emirates a high-risk nation that presents "strategic deficiencies in the anti–money laundering countering the financing of terrorism regimes". The move was taken amid the conflict against the Kinahan Organised Crime Group (KOCG), and was expected to push the authorities to take proactive measures against members of the Kinahan cartel. In July 2025, the European Commission revised its list of high-risk jurisdictions for money laundering and terrorism financing, which excluded the UAE. The European Parliament voted in favor of the updated list, which was earlier opposed by the MEPs. The decision to remove the Emirates from the EU money laundering blacklist was criticized by Transparency International, which said the country’s reforms cannot be considered effective yet. The EU listing process also came into question for not allowing the Parliament to assess the countries individually.
At the time, Senator Hatch's son was working for a firm hired to lobby Congress and the FDA on behalf of ephedra manufacturers. In addition to the activities of the Ephedra Education Council, Metabolife spent more than $4 million between 1998 and 2000 lobbying against state regulation of ephedra in Texas. Business Week reported that efforts to regulate ephedra and other potentially harmful supplements had been "beaten down by deep-pocketed industry lobbying." In 2000, the FDA withdrew the proposed labeling changes and restrictions.
=== Head and neck === Due to weakness of the muscles of facial expression and muscles of mastication, facial weakness may manifest as the inability to hold the mouth closed (the "hanging jaw sign") and as a snarling expression when attempting to smile. With drooping eyelids, facial weakness may make the individual appear sleepy or sad. Difficulty in holding the head upright may occur.
Sources: en.wikipedia.org
==== Supranational ==== United Nations: UN Assistance Mission in Afghanistan (UNAMA) urged both nations to cease hostilities and to take steps to prevent harm to civilians. Richard Bennett, the UN Special Rapporteur on the situation of human rights in Afghanistan, expressed concern over airstrikes in Nangarhar and Paktika, calling on the belligerent parties to exercise "maximum restraint". He stated deep concern for "a significant number of children and civilians" who were killed following the hostilities. European Union: In a brief statement, the EU Council called on all actors for immediate de-escalation and a halt of hostilities in the area. It reiterated to the Taliban that Afghan territory must not be used to threaten or attack other countries and calls on them to take effective action against all terrorist groups operating in or from Afghanistan.
Ethologist Jonathan Balcombe stated that female bonobos rub their clitorises together rapidly for ten to twenty seconds, and this behavior, "which may be repeated in rapid succession, is usually accompanied by grinding, shrieking, and clitoral engorgement"; he added that, on average, they engage in this practice "about once every two hours", and as bonobos sometimes mate face-to-face, "evolutionary biologist Marlene Zuk has suggested that the position of the clitoris in bonobos and some other primates has evolved to maximize stimulation during sexual intercourse". Many strepsirrhine species exhibit elongated clitorises that are either fully or partially tunneled by the urethra, including mouse lemurs, dwarf lemurs, all Eulemur species, lorises and galagos. Some of these species also exhibit a membrane seal across the vagina that closes the vaginal opening during the non-mating seasons, most notably mouse and dwarf lemurs. The clitoral morphology of the ring-tailed lemur is the most well-studied. They are described as having "elongated, pendulous clitorises that are [fully] tunneled by a urethra". The urethra is surrounded by erectile tissue, which allows for significant swelling during breeding seasons, but this erectile tissue differs from the typical male corpus spongiosum. Non-pregnant adult ring-tailed females do not show higher testosterone levels than males, but they do exhibit higher A4 and estrogen levels during seasonal aggression. During pregnancy, estrogen, A4, and testosterone levels are raised, but female fetuses are still "protected" from excess testosterone.
=== Fetal development impacts === Multiple epidemiological studies of people living in Europe, the United States, and China have linked in utero exposure to PAHs, through air pollution or parental occupational exposure, with poor fetal growth, reduced immune function, and poorer neurological development, including lower IQ.
Both Neanderthals and modern humans took care of the elderly members of their societies during the Middle and Upper Paleolithic. Some sources claim that most Middle and Upper Paleolithic societies were possibly fundamentally egalitarian and may have rarely or never engaged in organized violence between groups (i.e. war). Some Upper Paleolithic societies in resource-rich environments (such as societies in Sungir, in what is now Russia) may have had more complex and hierarchical organization (such as tribes with a pronounced hierarchy and a somewhat formal division of labor) and may have engaged in endemic warfare. Some argue that there was no formal leadership during the Middle and Upper Paleolithic. Like contemporary egalitarian hunter-gatherers such as the Mbuti pygmies, societies may have made decisions by communal consensus decision making rather than by appointing permanent rulers such as chiefs and monarchs. Nor was there a formal division of labor during the Paleolithic. Each member of the group was skilled at all tasks essential to survival, regardless of individual abilities. Theories to explain the apparent egalitarianism have arisen, notably the Marxist concept of primitive communism. Christopher Boehm (1999) has hypothesized that egalitarianism may have evolved in Paleolithic societies because of a need to distribute resources such as food and meat equally to avoid famine and ensure a stable food supply. Raymond C.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.